204 related articles for article (PubMed ID: 36685506)
21. M2 macrophage marker CHI3L2 could serve as a potential prognostic and immunological biomarker in glioma by integrated single-cell and bulk RNA-Seq analysis.
Qian W; Wang Q; Zhang C; Zhu J; Zhang Q; Luo C
J Gene Med; 2023 Sep; 25(9):e3523. PubMed ID: 37147894
[TBL] [Abstract][Full Text] [Related]
22. SEMA6B Overexpression Predicts Poor Prognosis and Correlates With the Tumor Immunosuppressive Microenvironment in Colorectal Cancer.
Li T; Yan Z; Wang W; Zhang R; Gan W; Lv S; Zeng Z; Hou Y; Yang M
Front Mol Biosci; 2021; 8():687319. PubMed ID: 34938771
[No Abstract] [Full Text] [Related]
23. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
[TBL] [Abstract][Full Text] [Related]
24. PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma.
Zhi W; Wang Y; Jiang C; Gong Y; Chen Q; Mao X; Deng W; Zhao S
Front Immunol; 2023; 14():1128244. PubMed ID: 37818357
[TBL] [Abstract][Full Text] [Related]
25. TREM1 as a novel prognostic biomarker and tumor immune microenvironment evaluator in glioma.
Lu Q; Xie Y; Qi X; Yang S
Medicine (Baltimore); 2023 Dec; 102(48):e36410. PubMed ID: 38050264
[TBL] [Abstract][Full Text] [Related]
26. Spinster homolog 2 reduces malignancies of glioblastoma via PTEN/PI3K/AKT pathway.
Liang W; Liu M; Su Y; Wen Y; Wang L; Shan J; Zhao J; Xie K; Wang J
IUBMB Life; 2024 Mar; 76(3):140-160. PubMed ID: 37728571
[TBL] [Abstract][Full Text] [Related]
27. Siglec15 is a prognostic indicator and a potential tumor-related macrophage regulator that is involved in the suppressive immunomicroenvironment in gliomas.
Wang J; Xu L; Ding Q; Li X; Wang K; Xu S; Liu B
Front Immunol; 2023; 14():1065062. PubMed ID: 37325664
[TBL] [Abstract][Full Text] [Related]
28.
Hu Z; Qu S
Front Immunol; 2021; 12():683572. PubMed ID: 34267752
[TBL] [Abstract][Full Text] [Related]
29. ARPC5 acts as a potential prognostic biomarker that is associated with cell proliferation, migration and immune infiltrate in gliomas.
Ming Y; Luo C; Ji B; Cheng J
BMC Cancer; 2023 Oct; 23(1):937. PubMed ID: 37789267
[TBL] [Abstract][Full Text] [Related]
30. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
Hao YP; Wang WY; Qiao Q; Li G
Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
[TBL] [Abstract][Full Text] [Related]
31. [The effect of HOXC10 gene on biological behaviors of glioma cells and mechanism in tumor microenvironment].
Jiang WY; Lei QY; Liu SS; Yang L; Yang B; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2022 Mar; 44(3):228-237. PubMed ID: 35316872
[No Abstract] [Full Text] [Related]
32. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
Liu J; Xu K; Ma L; Wang Y
Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
[TBL] [Abstract][Full Text] [Related]
33. GRN is a prognostic biomarker and correlated with immune infiltration in glioma: A study based on TCGA data.
Xu SM; Xiao HY; Hu ZX; Zhong XF; Zeng YJ; Wu YX; Li D; Song T
Front Oncol; 2023; 13():1162983. PubMed ID: 37091137
[TBL] [Abstract][Full Text] [Related]
34. The pro-invasive factor COL6A2 serves as a novel prognostic marker of glioma.
Zhu J; Lin Q; Zheng H; Rao Y; Ji T
Front Oncol; 2022; 12():897042. PubMed ID: 36505882
[TBL] [Abstract][Full Text] [Related]
35. High Expression of CISD2 in Relation to Adverse Outcome and Abnormal Immune Cell Infiltration in Glioma.
Zhang F; Cai HB; Liu HZ; Gao S; Wang B; Hu YC; Cheng HW; Liu JX; Gao Y; Hong WM
Dis Markers; 2022; 2022():8133505. PubMed ID: 35493303
[TBL] [Abstract][Full Text] [Related]
36. PROS1, a clinical prognostic biomarker and tumor suppressor, is associated with immune cell infiltration in breast cancer: A bioinformatics analysis combined with experimental verification.
He T; Sun X; Wu C; Yao L; Zhang Y; Liu S; Jiang Y; Li Y; Wang M; Xu Y
Cell Signal; 2023 Dec; 112():110918. PubMed ID: 37827342
[TBL] [Abstract][Full Text] [Related]
37. SARS-CoV-2 Pattern Provides a New Scoring System and Predicts the Prognosis and Immune Therapeutic Response in Glioma.
Jiang F; Lu DF; Zhan Z; Yuan GQ; Liu GJ; Gu JY; Sun XO; Wang Z
Cells; 2022 Dec; 11(24):. PubMed ID: 36552760
[TBL] [Abstract][Full Text] [Related]
38. Matrix Remodeling-Associated Protein 8 as a Novel Indicator Contributing to Glioma Immune Response by Regulating Ferroptosis.
Xu Z; Chen X; Song L; Yuan F; Yan Y
Front Immunol; 2022; 13():834595. PubMed ID: 35281049
[TBL] [Abstract][Full Text] [Related]
39.
Gao X; Liu Y; Hong S; Yang H; Guan B; Ma X
J Integr Neurosci; 2023 Aug; 22(5):135. PubMed ID: 37735118
[TBL] [Abstract][Full Text] [Related]
40. Grade II/III Glioma Microenvironment Mining and Its Prognostic Merit.
Chen J; Hou C; Wang P; Yang Y; Zhou D
World Neurosurg; 2019 Dec; 132():e76-e88. PubMed ID: 31518750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
